Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates potent POLRMT degradation using mitochondrial protease targeting chimeras in cancer models, indicating a viable modality for targeting mitochondrial proteins.
Despite the broad success of targeted protein degradation (TPD), achieving efficient degradation within mitochondria remains a challenge. Herein, we report a highly active degrader targeting human mitochondrial RNA polymerase (POLRMT) based on the Mitochondrial Protease Targeting Chimeras (MtPTACs) strategy. The lead compound, MTP-B1, is a highly potent MtPTAC to achieve essentially complete target degradation (Dmax > 98%) within 24 h at sub-micromolar concentrations. Mechanistically, MTP-B1 circumvents the compensatory transcriptional upregulation induced by POLRMT inhibitors and sustains downstream signaling suppression in washout assays. Remarkably, under the dosing regimens tested, MTP-B1 exhibited greater in vivo antitumor efficacy than the co-administration of a POLRMT inhibitor and a ClpP activator, highlighting the therapeutic potential of targeted protein degradation in mitochondria. These findings, further supported by the extension to a second target, dihydroorotate dehydrogenase (DHODH), provide high-efficiency MtPTACs as a powerful and generalizable modality for mitochondrial medicine.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: